- Home
- KLAR vs PCVX Comparison
KLAR vs PCVX Comparison
Compare KLAR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLAR | PCVX |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.0B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KLAR | PCVX |
|---|---|---|
| Price | $13.38 | $65.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 11 |
| Target Price | $19.54 | ★ $114.78 |
| AVG Volume (30 Days) | ★ 5.0M | 2.7M |
| Earning Date | 11-17-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.72 | N/A |
| Revenue Next Year | $15.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $39.87 |
| 52 Week High | $41.64 | $90.75 |
Technical Indicators
Market Signals| Indicator | KLAR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 58.84 |
| Support Level | $12.28 | $48.67 |
| Resistance Level | $15.22 | N/A |
| Average True Range (ATR) | 0.43 | 4.26 |
| MACD | 0.17 | 1.06 |
| Stochastic Oscillator | 57.19 | 30.59 |
Price Performance
Historical ComparisonAbout KLAR Klarna Group plc Ordinary Shares
Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.